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Abstract
Background: Thyroid cancer has the fastest growing incidence in the US. However, the underlying causes are still
under debate.
Methods: We analyzed thyroid cancer incidence in the SEER-9 registry from 1973-2010 using multistage carcinogenesis
and age-period-cohort models. Multistage models were used to investigate differences in initiation, promotion and
malignant conversion rates of thyroid tumors by sex, race, stage, and histology. Models were adjusted for period and
cohort trends to investigate the contributions of each factor, and determine whether birth- or diagnosis-year better
correlate with observed incidence patterns.
Results: Significant increases in thyroid cancer incidence by period or calendar-year were found for all sex, race, stage
and histology combinations, particularly for localized cases (a 3- and 4-fold increase from 1973-2010 for females and
males, respectively). Multistage analyses suggest that the 3-fold higher incidence in women could be explained by
1.5-fold higher initiation and promotion rates. Analyses by race suggest that the lower incidence in blacks can be
attributed to lower promotion rates versus whites. Analysis by histology showed considerable decreases in follicular
cancer incidence by birth-cohort since the early 1900s.
Conclusions: Multistage modeling suggests that variations in thyroid cancer initiation and promotion can explain the
observed differences in incidence by sex, race and histology. The consistent increases in incidence by calendar-year for
all sex-race-histology-stage combinations suggest that the rise may be predominantly due to more intensive
screening-diagnostics, although an environmental factor may be also at play. Our analyses constitute a first step
towards the development of thyroid cancer natural history models.
Background
Thyroid cancer incidence worldwide has increased dra-
matically during the past three decades. Specifically,
global age-standardized thyroid cancer incidence rates
have increased 3-fold for both women and men since
the 1970s, although with geographical variations [1].
Multiple descriptive studies have reported the upward
trend of thyroid cancer [2–7]. However, the underlying
causes are still under debate, with some attributing the
increase to the widespread use of ionizing radiation
therapy for head and neck benign conditions among
children and adolescents back in the 1920-1950s [8, 9],
while others attributing it to improvements in diagnos-
tic tests and increase surveillance [10, 11].
The etiology of thyroid cancer is not fully understood,
nonetheless it has been shown that gender and exposures
to high-levels of ionizing radiation are major risk factors
[12–14]. In terms of gender, thyroid cancer has become
the fifth most common cancer among women in the
United States [15], with a female to male ratio of 3:1. The
gender imbalance has been attributed among other rea-
sons to female hormonal and reproductive factors, which
correlate with the age-specific rise in female thyroid
cancer incidence around the age of menarche and the
decrease or slow-down after menopause [1, 16]. With
regards to ionizing radiation, previous studies have shown* Correspondence: rmeza@umich.edu
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that atomic bomb survivors and children living in con-
taminated areas around Chernobyl in 1986 experienced
particularly high rates of thyroid cancer. In addition, other
studies have suggested that levels of iodine could be a risk
factor for thyroid cancer. For example, patients with goi-
ter, which suffer from iodine deficiency, have high rates of
thyroid cancer [17]. There is also evidence that low levels
of iodine in the diet associate with follicular thyroid
cancers, whereas high levels are associated with papillary
thyroid cancers [12].
Thyroid cancer has the fastest growing incidence in
the US. Various authors have suggested that the rise in
thyroid cancer incidence in the US is predominantly due
to increases in surveillance and diagnostic improvements
for detecting smaller tumors [2–4]. Other interpretations
suggest that diagnostic scrutiny is not fully responsible
for the increasing trends, but rather that there could be
due to other factors like increases in obesity and changes
in diet and physical activity [5–7] or exposures to envir-
onmental agents like radiation, Bisphenol A, and poly-
brominated biphenyl ethers [18–20]. Independently of
the underlying reasons, thyroid cancer has become the
fifth most common cancer in US women and has be-
come significant public health issue.
Significant differences in thyroid cancer risk by race in
the US have been reported [4, 21, 22], with whites hav-
ing about twice the incidence than blacks. Healthcare ac-
cess and socioeconomic status (SES) have been shown to
be positively associated with thyroid cancer incidence,
likely due to better detection and surveillance [4, 23].
Thus several authors have suggested that differences in
SES by race may explain the lower thyroid cancer inci-
dence in blacks [4, 23, 24]. However, it has been shown
that differences in health care access between blacks and
whites only explain partly the racial gap in thyroid can-
cer [24], and that increasing trends are similar between
whites and blacks [16, 25]. Therefore other mechanisms,
like racial variations in susceptibility and differences in
exposures to environmental agents could be also respon-
sible for the observed disparities [24, 26].
Several studies have previously examined thyroid can-
cer trends in SEER using descriptive analyses, joinpoint
regression and APC models [2, 3, 16, 25]. Here we ex-
tend those analyses and complement them using multi-
stage modeling that provides additional insights in terms
of the biologicals mechanism of initiation, promotion
and malignant conversion [27–33].
In this paper we investigated thyroid cancer incidence
trends by sex, race, and stage in the US using multistage
carcinogenesis models and age-period-cohort (APC)
analysis. Multistage thyroid carcinogenesis models were
used to investigate potential differences in initiation,
promotion and malignant conversion rates by sex, race,
stage and histology. Models were adjusted for period
and birth-cohort trends to investigate the contributions
of each of these factors, and to examine whether birth-
or diagnosis-year better correlate with observed inci-
dence patterns.
Materials and methods
Data sources
Thyroid cancer incidence data was obtained from the
Surveillance, Epidemiology, and End Results (SEER)-9
registries for the years 1973–2010. We extracted re-
ported thyroid cancer cases by sex, race, age, stage, hist-
ology and calendar year in the nine SEER geographic
areas, which together represent an estimated 9.5 % of
the U.S. population [34]. Thyroid cancer cases were
coded using the International Classification of Diseases
for Oncology, third edition (ICD-O-3) [35]. We re-
stricted our analysis by histology to papillary (8050,
8052, 8130, 8260, 8340-8344, 8450, 8452) and follicular
(8290, 8330-8332, 8335) types. Person-years by sex, race,
age, and calendar year were obtained from the SEER
registry. We analyzed combined thyroid cancer inci-
dence to allow for race/gender comparisons, and also
perform independent analyses by histology for all males
and all females separately.
Multistage model and age-period-cohort analyses
We performed likelihood-based analyses of the incidence
of thyroid cancer in the SEER registries using APC
models, where we replaced the non-specific age effects
of traditional APC analyses with the hazard of multistage
models. Secular trends, i.e., period and cohort effects,
were modeled in the usual fashion as described below
[28, 31, 32]. This approach constrains the age-effects
parametrically and solves in principle the non-
identifiability issues of APC models allowing us to esti-
mate jointly the age, period and cohort trends [36].
Briefly, the thyroid cancer age-specific incidence at age a
occurring in calendar year j is modeled as:
hij að Þ¼bicjh að Þ;
where h(a) is the Two-Stage Clonal Expasion (TSCE)
model hazard described below, cj is a coefficient that ad-
justs for calendar year j, and the coefficient bi adjusts for
birth cohort i (i = j-a , stratified in 5-year groups; <1890,
1890–1894,… ,1985-1990, and ≥1991). We used single
ages from 0-84 and single calendar years from 1973-
2010. We then fitted the model to the number of
observed thyroid cancer cases (papillary and follicular
combined) stratified by age and calendar-year. We ob-
tained parameter estimates by maximizing the likeli-
hood across all age-calendar strata assuming that the
number of cases in each stratum is Poisson distributed
with mean Nij*hij(a), where Nij is the population at risk
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in age group i and birth cohort j, and hij(a) is as defined
above. Separate analyses for all sex, race, stage, and
histology combinations were also performed. Multistage
model analyses were done using the Bhat likelihood
minimization package in R (R version 3.0.3).
In addition, we also fitted traditional APC models for
comparison using the Epi package in R [37], and per-
formed a joinpoint regression analysis using the sta-
tistical software Joinpoint, version 3.5 (Surveillance
Research Program, US National Cancer Institute) [38] to
characterize trends in age-adjusted incidence rates by
sex, race, histology, and stage.
Two-stage clonal expansion model
The TSCE model posits that cells initiated via a Poisson
process undergo clonal expansion and malignant conver-
sion via a birth–death–mutation process, and is based
on the initiation-promotion-malignant conversion para-
digm in carcinogenesis. The details of this model are
presented elsewhere [27, 29]. Although the TSCE model
is a simplification of the carcinogenesis and does not ne-
cessarily incorporate current knowledge about the nat-
ural history of thyroid cancer, it does capture the main
aspects of tumor initiation-promotion and malignant
conversion and thus has been used to analyze the tem-
poral trends of a variety of cancers. In particular, this
model and its generalizations have been used to analyze
the incidence of a variety of cancers in SEER including
colorectal cancer [28, 31, 33] esophageal cancer [30, 36],
mesothelioma [32], and pancreatic cancer [31]. The
TSCE model has four biological parameters: the rate of
initiation, μ0X, the rate of division, a, and death, b, of
initiated cells, and the rate of malignant conversion, μ1.
Figure 1 shows a schematic representation of the TSCE
model. Not all four parameters can be estimated from
cancer incidence data alone. We estimated three iden-
tifiable parameters as described below. With constant
parameters, the hazard function for this model takes the
following form:
h tð Þ ¼ μ0X
a
pq
e−qt−e−pt
qe−pt−pe−qt
where p and q are the roots of a quadratic equation,
with p + q = -g = -(a - b-μ1) and p*q = a*μ1. We estimated
p(≈-g), q, and r = μ0X/a ; which comprise a set of identifi-
able parameters. Note that p is roughly the net rate of pro-
liferation of initiated cells (since μ1 is a mutation rate and
thus much smaller than a and b ), q ~ μ1/(1-b/a), and r is
related to the rate of tumor initiation.
Results
66,144 thyroid cancer cases were diagnosed from 1973
to 2010 in the SEER 9 registry areas, including 49,471 fe-
males and 16,673 males. The majority of cases occurred
in whites (n = 40,379; 81.6 %) and papillary histological
type (n = 53,809; 81.3 %). Regarding stage, 59.2 % of
cases were diagnosed as localized, 32.7 % cases as re-
gional, and 5.1 % cases as distant.
Figure 2 shows the estimated TSCE model hazards
(age-specific incidence) by sex and race (all thyroid can-
cers combined) after removal of period and cohort ef-
fects (left- panel). In all cases the hazard starts at zero,
grows slowly until becoming exponentially increasing
and then slows down eventually reaching an asymptote
(equal to -r*p). The age-specific thyroid cancer incidence
is about 1.5-2.0 times higher in whites than blacks, and
2.5-3.0 times higher in women than in men. The right
panel shows the estimated thyroid cancer TSCE model
hazards by stage and sex (all races combined). We find
b
Normal
X Initiated
Thyroid 
Cancer
a
µ0 µ1
Initiation
Malignant
conversion
clonal expansion
of initiated cells
Cell death
Fig. 1 Two-stage clonal expansion (TSCE) carcinogenesis model
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Fig. 2 Thyroid cancer hazard (age-specific incidence) by race,
gender and stage - TSCE-P-C thyroid cancer model
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that in both men and women the exponential increase in
the age-specific incidence appears to start at younger
ages for earlier stages, but that the asymptote is reached
at younger ages for more advanced stages. So the range
of exponential increase in age-specific risk is the longest
for localized cancers and shortest for distant cancers.
Table 1 shows the estimated TSCE model biological
parameters (r, p and q) by gender, race, stage and hist-
ology. As described above r is a measure of tumor initi-
ation, -p represents the net cell proliferation of tumor
cells, so it is a measure of premalignant tumor growth
or promotion rate, and q is proportional to the malig-
nant conversion rate. The table shows that the estimated
initiation and promotion rates are consistently higher in
women, whereas the malignant conversion rate is higher
in men, and that promotion rates are about two-fold
higher in whites versus blacks. Initiation rates decrease
significantly by stage, explaining the higher age-specific
incidence for earlier stages observed in Fig. 2. Whereas
the estimated promotion rates, i.e., tumor growth rates,
increase with stage, explaining the faster increase toward
the asymptote for advanced stages in Fig. 2. In addition,
there is no significant difference in biological parameters
between papillary and follicular histologies.
To assess if year of diagnosis (period) or year of birth
(cohort) is more relevant in determining thyroid cancer
risk, we also fitted two-effect models (TSCE-Period or
TSCE-Cohort) and compared their goodness-of-fit using
the Akaike Information Criteria (AIC) [39]. Table 2
shows that in general the TSCE-Period models give a
significantly better fit the data according to the AIC than
the TSCE-Cohort models, suggesting that period or
calendar-year better correlate with thyroid cancer inci-
dence (with the possible exception of distant cancers,
and cancers in black males). The table also shows the
AICs for models that estimate both period and cohort
effects simultaneously (TSCE-PC), which give the overall
best fit and are therefore the preferred models.
Figure 3 shows the estimated period (calendar-year)
and cohort (birth-year) effects from the final TSCE-PC
models by race and sex (all thyroid cancers combined).
Significant increases in thyroid cancer incidence by
calendar-year (period) starting in the late 1980s are ob-
served for all groups (~3-fold for females and ~ 4-fold
Table 1 TSCE thyroid cancer incidence model parameter estimates
Parameter r 95 % CI -p 95 % CI q 95 % CI
Female 3.87E-04 3.46E-04 4.33E-04 2.49E-01 2.35E-01 2.49E-01 9.39E-04 7.73E-04 1.14E-03
Male 2.82E-04 2.24E-04 3.54E-04 1.68E-01 1.44E-01 1.95E-01 2.76E-03 2.02E-03 3.78E-03
White female 3.64E-04 3.22E-04 4.11E-04 2.59E-01 2.44E-01 2.76E-01 8.22E-04 6.62E-04 1.02E-03
White male 2.66E-04 2.08E-04 3.40E-04 1.71E-01 1.45E-01 2.00E-01 2.69E-03 1.91E-03 3.79E-03
Black female 4.26E-04 2.42E-04 7.49E-04 1.68E-01 1.22E-01 2.28E-01 1.97E-03 1.08E-03 3.57E-03
Black male 1.98E-04 7.90E-05 4.15E-04 9.73E-02 6.78E-02 1.37E-01 2.52E-03 1.01E-03 6.24E-03
Tumor stage
Female
Localize 3.58E-04 3.10E-04 4.13E-04 2.15E-01 2.00E-01 2.31E-01 8.51E-04 6.86E-04 1.06E-03
Regional 6.62E-05 5.36E-05 8.18E-05 3.05E-01 2.78E-01 3.34E-01 7.37E-04 5.09E-04 1.07E-03
Distant 9.52E-06 5.29E-06 1.71E-05 3.42E-01 2.13E-01 4.99E-01 3.45E-03 1.05E-03 1.13E-02
Tumor stage
Male
Localize 2.20E-04 1.58E-04 3.06E-04 1.44E-01 1.18E-01 1.74E-01 2.15E-03 1.51E-03 3.05E-03
Regional 6.43E-05 4.64E-05 8.91E-05 2.16E-01 1.75E-01 2.64E-01 1.86E-03 1.05E-03 3.31E-03
Distant 8.60E-06 3.94E-06 1.87E-05 3.37E-01 1.71E-01 5.57E-01 2.38E-03 3.40E-04 1.64E-02
Histology
Female
Papillary 2.84E-04 2.50E-04 3.23E-04 2.63E-01 2.47E-01 2.80E-01 7.70E-04 6.15E-04 9.62E-04
Follicular 5.44E-05 3.91E-05 7.57E-05 2.57E-01 2.14E-01 3.06E-01 1.09E-03 5.86E-04 2.03E-03
Histology
Male
Papillary 1.77E-04 1.40E-04 2.24E-04 2.00E-01 1.72E-01 2.30E-01 1.76E-03 1.19E-03 2.60E-03
Follicular 1.13E-04 8.68E-05 1.48E-04 1.50E-02 7.56E-01 1.50E-01 2.22E-03 1.38E-03 3.59E-03
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for males). The increases by period are quite consistent
by race for both females and males. The estimated birth-
cohort effects are harder to interpret, but suggest a
consistent decrease in incidence for more recent birth-
cohorts, which is overshadowed by the significant
increases by calendar-year.
Figure 4 shows observed versus predicted age-specific
thyroid incidence by gender for selected years and co-
horts. The predicted curves are constructed by multiply-
ing the estimated TSCE hazard, by the corresponding
period and cohort effects. The figure shows that the
models do capture the age and time trends observed in
the data. Additional figures comparing the models by
race and gender and observed data are shown in the
supplementary material (Additional file 1: Figures S7
and S8).
Figure 5 shows the estimated hazards (age-specific in-
cidence) by histology (papillary and follicular) after re-
moval of period and cohort effects. The age-specific
incidence for papillary histology is about 3.5-4 and 2
times higher than that of follicular histology in females
and males, respectively, with the papillary incidence be-
ing considerably much higher in females versus males.
We find that for both histologies the exponential
Table 2 Akaike information criteria (AICa) values for TSCE
models relative to the TSCE/P modelb
Relative AIC TSCE/P TSCE-P-C TSCE/C
Females 0 -465.84 1215.04
Males 0 -177.24 145.14
White females 0 -540.56 974.3
White males 0 -157.3 113.076
Black females 0 -21.116 12.774
Black males 0 16.076 -18.528
Tumor stage (Females)
Localized 0 -777.6 438.8
Regional 0 -88.16 463.04
Distant 0 -1.092 -4.488
Tumor stage (Males)
Localized 0 -95.136 202.464
Regional 0 -55.4308 28.659
Distant 0 20.168 4.128
TSCE two-stage clonal expansion model, TSCE/P TSCE period; TSCE/C, TSCE
cohort; TSCE-P-C, TSCE period-cohort
a -2 × log(likelihood) + 2 × number of estimated parameters
b Relative values that weight the goodness of fit of the model to empirical
data. The lower the AIC, the better the model fit
Fig. 3 Thyroid cancer incidence period and cohort trends by gender and race – TSCE-P-C thyroid cancer model
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increase in the age-specific incidence starts at a younger
age in females. Figure 6 shows the estimated period and
cohort trends by histological type. Significant increases
in thyroid cancer incidence by calendar-year starting in
the late 1980s are observed for both histologies, mim-
icking the trends found for all thyroid cancers. Cohort
trends for papillary cancers by gender resemble those
for all thyroid cancers, whereas for follicular cancer co-
hort trends are decreasing for cohorts starting since the
early 1900s. Observed versus predicted thyroid cancer
incidence figures by histology are shown in the supple-
mental material (Additional file 1: Figures S9 and S10).
Results of standard APC analyses for all thyroid can-
cers are also shown in the appendix. Overall, these show
roughly consistent results with the multistage model
analyses, particularly for the period trends, and suggest
that period rather than cohort is more relevant in deter-
mining thyroid cancer risk. Joinpoint analysis results are
also shown in the appendix and show consistent trends
by calendar year as found with the multistage models.
Discussion
In this paper we investigated thyroid cancer incidence
trends by sex, race, stage and histology in the US using
multistage carcinogenesis and age-period-cohort models.
Our analyses suggested that period rather than cohort is
more significant in determining thyroid cancer rates,
with the possible exception of distant cancers, and that
the increase of thyroid cancer by calendar-year is con-
sistent for all sex, race, and histology combinations ana-
lyzed. These results together with the observation from
joinpoint analyses (appendix) showing that the largest
recent increases have occurred primarily for localized
Fig. 4 Observed versus modeled age-specific thyroid cancer rates by period and cohort
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Fig. 5 Thyroid cancer TSCE hazard by histology
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cancers suggest that the rising incidence may be predom-
inantly due to more intensive surveillance and improved
diagnostics. Nonetheless, the consistent calendar-year in-
creases by race, which have occurred in presence of sig-
nificant disparities in health care access by socioeconomic
status and race [4, 23, 24], suggest that an environmental
factor may be also at play.
Previous analyses have compared thyroid cancer inci-
dence trends by sex, stage, and race using joinpoint and
APC models [2, 3, 16, 25, 40]. Here we complement these
with multistage modeling analyses, which allowed us to
generate hypotheses about the biological mechanisms of
thyroid cancer tumor initiation, promotion and malignant
conversion. For instance, the multistage analyses show
that the 3-fold higher thyroid cancer incidence in women
versus men can be explained by 1.5-fold higher rates of
initiation and promotion (premalignant tumor growth).
These imply that women get 50 % more tumors and that
those progress 50 % more rapidly to cancer than men’s.
The lower thyroid cancer incidence in blacks can be attrib-
uted in part to lower tumor promotion rates versus whites.
Sub-analyses of thyroid cancer incidence by stage reveal
gradients of tumor initiation (localized > regional > distant)
and promotion (localized < regional < distant) that suggest
heterogeneity in aggressiveness from tumor onset with
clear implications for the overdiagnosis of slow growing
tumors under active screening and surveillance.
The estimated TSCE hazards (age-specific incidence)
display a pattern where the asymptote is reached in mid-
dle age (roughly flat after age 40). This appears to be in
contrast with previous analyses of thyroid cancer based
on age-period-cohort models that have found age-
specific patterns by period that decrease after age 40, or
by cohort that increase until age 70 [40]. Our results are
indeed consistent with these previous findings, once the
TSCE hazards are multiplied by the corresponding esti-
mated period and cohort effects as shown in Fig. 4 (and
Additional file 1: Figures S7, S8, S9 and 10s). This sug-
gests that a constant age-specific thyroid cancer risk
from age 40-50 is consistent with the SEER data, and
that the observed decreases in age-specific risk in differ-
ent years (period) or increases in age-specific risk until
late in life by cohort, might just be representing un-
adjusted secular trends and not true age patterns in risk.
Analyses of thyroid cancer incidence by histological
type (papillary vs follicular) show that interestingly esti-
mated promotion rates do not seem to vary by histology,
but that initiation of papillary cancers is about 6 and 1.5
times higher than that of follicular cancers in females
and males, respectively. The higher initiation rates could
Fig. 6 Thyroid cancer incidence period and cohort trends by histology and gender
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be attributed to higher underlying mutation rates or to a
higher number of susceptible cells. Interestingly, the es-
timated period effects do not vary much by histology,
suggesting a common risk factor or an underlying cause
behind the thyroid cancer increase with calendar year
(potentially increased screening). However, the estimated
birth-cohort effects do vary by histology, and show a de-
creasing trend for follicular cancers since the early 1900s
possibly reflecting the reductions in risk due to
iodization of salt in the US [41].
Our study has several limitations. First, in common
with other analyses of cancer registry data, we were un-
able to assess exposures to relevant risk factors, such as
dietary patterns and environmental exposures, in the
underlying population and cancer cases. Nonetheless,
the SEER registry allowed us to analyze trends in thyroid
cancer incidence since the 1970s by sex, race, stage and
histology. Second, our multistage models are clearly a
simplification of the underlying biology of thyroid cancer
incidence and neglect the contribution of relevant risk
factors. As mentioned above, this is largely due to the
lack of risk factor data from the SEER cancer registry.
However, the age-period-cohort approach allowed us to
control for secular trends in the estimation of the bio-
logical parameters. Moreover, the estimated TSCE
models provide better fits to the data than more com-
plex models that allow for additional carcinogenesis
stages (data not shown), and the differences in biological
parameters provide plausible explanations to the ob-
served differences in age-specific thyroid cancer risk.
Third, age-period-cohort models have an inherent non-
identifiability problem that makes it impossible to esti-
mate uniquely the period and cohort effects [42, 43].
However, replacing the age effects with the hazard of a
multistage model resolves, at least in theory, the non-
identifiability problem, allowing us to estimate uniquely
the secular trends [36]. Finally, the smaller sample sizes
for some demographic groups, like black males, or for
specific histologies, like follicular cancer in men, pre-
clude us from doing more detailed analyses.
Conclusions
In summary, our analyses provide additional evidence
that indicates that the rise in thyroid cancer incidence is
likely predominantly due to more intensive screening-
diagnostics, but also suggest that an environmental fac-
tor could be also at play. Given the recent evidence that
indicates that current screening and imaging practices
have led to significant levels of thyroid cancer overdiag-
nosis in the US [44, 45], there is a need to develop thy-
roid cancer natural history models to quantify the
impact of such practices on observed thyroid cancer
rates. Such models could be also used to investigate the
potential impact of interventions to reduce thyroid
cancer incidence and mortality and to predict the poten-
tial benefits (and harms) of changes in surveillance and
screening practices on thyroid cancer outcomes [46, 47].
The models developed here constitute a first step in that
direction [31, 33, 46].
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